The management of cystic fibrosis. Observations on gentamycin when used with other antibiotics in pulmonary infections associated with cystic fibrosis.

From 1971 to 1973, we hospitalized 41 symptomatic patients with cystic fibrosis 
for intensive pulmonary therapy. The more severely ill patients were admitted 
more than once during this period. Our study included 100 courses 
of such intensive treatment. Garamycin pediatric injectable, containing 10 mg/ml of 
the active ingredient, was administered intravenously to all patients in divided 
doses of 3.0 to 5.0 mg/kg/day. The purpose of the study 
was to evaluate the tolerance, pharmacokinetics, and efficacy of garamycin when 
administered parenterally to cystic fibrosis patients with serious infections. During the 
100 courses of treatment, clinical improvement was rated as follows: significant 
or definite improvement, 39; moderate improvement, 50; slight improvement, 9; and 
no change, 2. The use of garamycin pediatric injectable is safe 
and can be helpful in the management of the pulmonary infectious 
complications of cystic fibrosis when employed along with other well-established modalities 
of therapy. 